Replies to post #190876 on Biotech Values

[ChikiTiny]

what a great call end of last year Dew! Seems like EGRX still has substantially more upside even from here.

[DewDiligence]

Added EGRX today for the same reason—playing a hunch about a deal with MDCO on Angiomax (#msg-113377784). Still a relatively small position.

It’s annoying to buy a stock after it has tripled (since the Trenda settlement with Teva in February: #msg-110943484), but sometimes it’s the right decision. If EGRX inks a deal with MDCO for its ready-to-infuse formulation of Angiomax, the share price is certainly going higher.

[DewDiligence]

EGRX submits 505b2 NDA for ready-to-use Angiomax formulation:

http://finance.yahoo.com/news/eagle-pharmaceuticals-submits-nda-ready-105000836.html

…our liquid formulation will allow for immediate administration, with no reconstitution nor initial dilution required, reducing work flow and the risk of dosing errors. We believe these attributes of our formulation can be clinically significant in critical care situations.

…Eagle’s intellectual property pertaining to RTU bivalirudin includes two issued patents and an additional patent pending at the U.S. Patent and Trademark Office.

Branded Angiomax from MDCO is lyophilized, and hence it must be reconstituted before use, exposing the hospital staffer to toxic fumes. Moreover, Angiomax is used in the ER, where the reconstitution may have to be done under time pressure by an ER nurse.